Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mens rea proof may be key to Daiichi legal action against Singh bros amid war of words

This article was originally published in Scrip

Executive Summary

Was it alleged deception, connivance of the top brass, mens rea or then perhaps sheer lax due diligence that did for Japan's Daiichi Sankyo when it acquired Ranbaxy Laboratories in 2008 even as US regulators were deep-probing the company for violations concerning data integrity and GMP issues?

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021488

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel